Skip to content

UroGen Pharma URGN Gross Profit

Discontinued — last reported Q2 '21

Gross Profit at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$8.07B-1.2%
Pfizer logo
PfizerPFE
$10.9B+0.3%
Johnson & Johnson logo
Johnson & JohnsonJNJ
$15.96B+9.8%
Merck & Co. logo
Merck & Co.MRK
$12.09B-0.2%
LQD
Liquidia CorporationLQDA
$1.6M+6.5%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX

Other financials

Income statement

See full
Revenue$51.0M+152%
Operating income-$22.8M
Net income-$23.6M+46.2%
EPS (diluted)-$1.17

Balance sheet

See full
Cash & equivalents$110.0M+5.7%
Total debt$197.1M+56.0%
Total equity-$124.3M-167%
Total assets$253.7M+2.5%

Cash flow

See full
Operating cash flow-$45.3M-7.8%
CapEx$54.0K+22.7%
Free cash flow-$45.4M-7.8%

Valuation

See full
Market cap$1.71B+71.7%
Enterprise value$1.8B+80.9%
P/S12.2×+1.3×

Profitability

See full
Gross margin89.7%
Operating margin-329.7%
Net margin-94.8%-25.6pp
FCF margin-118.2%+1.3pp

Returns & leverage

See full
Return on equity-211.6%
Debt / equity4.8×
Current ratio4.7×-1.0×

Where this comes from

Calculated from UroGen Pharma’s reported figures.

The official record: UroGen Pharma’s 10-Q, filed August 4, 2021, on SEC EDGAR. View the filing →

Ask your AI about UroGen Pharma's gross profit.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is UroGen Pharma's gross profit?
UroGen Pharma (URGN) reported gross profit of $11.61M in Q2 2021.
What does gross profit mean?
Revenue minus cost of revenue — the profit available to cover operating expenses, representing the company's pricing power and production efficiency.